Clinical Trial Update: Panobinostat (LBH589) in Patients With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study of panobinostat (LBH589) in patients with metastatic melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma, Malignant Melanoma | Phase 1 | Status: COMPLETED